Intellipharmaceutics (IPCI) 1.99

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Intellipharmaceutics (IPCI) 1.99 $IPCI

Intellipharmaceutics Closes Public Offering for US$5.2 Million
GlobeNewswire - Mon Jun 06, 4:30PM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today the closing of its previously announced underwritten public offering of 3,229,814 units of common shares and warrants, at a price of US$1.61 per unit, for gross proceeds of approximately US$5.2 million. The Company sold units comprised of an aggregate of 3,229,814 common shares and warrants to purchase an additional 1,614,907 common shares. The underwriter also purchased additional warrants to acquire 240,390 common shares pursuant to the over-allotment option exercised in part by the underwriter. The warrants are exercisable immediately, have a term of five years and an exercise price of US$1.93 per common share. After underwriting discounts and commissions and estimated offering expenses, the Company received net proceeds of approximately US$4.6 Million.
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

IIROC Trade Resumption - I
CNW Group - Fri May 27, 8:45AM CDT
Trading resumes in:
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

IIROC Trade Resumption - Intellipharmaceutics International Inc.
Newsfile Corp - Fri May 27, 8:42AM CDT
Trading resumes in:
IPCI: 1.99 (+0.15)

IIROC Trade Halt - Intellipharmaceutics International Inc.
Newsfile Corp - Fri May 27, 8:31AM CDT
The following issues have been halted by IIROC:
IPCI: 1.99 (+0.15)

Intellipharmaceutics Announces Pricing of $5.2 Million Public Offering of Common Shares and Warrants
GlobeNewswire - Fri May 27, 8:30AM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced the pricing of an underwritten public offering of 3,229,814 units of common shares and warrants, at a price of US$1.61 per unit, equal to the closing price of the Company's shares on the NASDAQ on May 26, 2016. In connection with the offering, the Company will be issuing an aggregate of 3,229,814 common shares and warrants to purchase an additional 1,614,907 common shares. The warrants will be exercisable immediately, have a term of five years and an exercise price of US$1.93 per common share. After underwriting discounts and commissions and estimated offering expenses, the Company expects to receive net proceeds of approximately US$4.6 million.
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

IIROC Trading Halt - I
CNW Group - Fri May 27, 8:30AM CDT
The following issues have been halted by IIROC:
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

Intellipharmaceutics Announces Proposed Public Offering of Units of Common Shares and Warrants
GlobeNewswire - Thu May 26, 4:24PM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it intends to offer units of its common shares and warrants in an underwritten public offering. Dawson James Securities, Inc. is acting as sole bookrunner for the offering. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

Intellipharmaceuticals International's CFO Domenic Della Penna Interviewed by The Life Sciences Report
Marketwired - Thu May 12, 8:02AM CDT
SAN FRANCISCO, CA--(Marketwired - May 12, 2016) -  Opioid abuse has moved front and center in the political and social arena, sparked in recent weeks by the still-unexplained death of music legend Prince. Heroin is the headline, but addiction to prescription painkillers, like those reportedly used by the pop icon to control chronic pain, runs a close second. How can the biotech industry deter abuse of drugs like oxycodone? Intellipharmaceutics International Inc.  (NASDAQ: IPCI) (TSX: I) has a potential solution, Chief Financial Officer Domenic Della Penna tells The Life Sciences Report, as well as a robust pipeline of generic options for a variety of indications.
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

Intellipharmaceutics Reports Director Election Results
GlobeNewswire - Tue Apr 19, 4:30PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, reports, as required by TSX rules, that the six nominees, each of whom was an incumbent director of the Company, identified in the Management Information Circular dated March 11, 2016 (the "Circular" were elected as directors of the Company at the annual and special meeting of shareholders of the Company held today (the "Meeting". The voting results, as set out in the scrutineer's report for the Meeting, were as follows:
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

Intellipharmaceutics Announces First Quarter 2016 Results
GlobeNewswire - Fri Apr 15, 5:30AM CDT
Intellipharmaceutics International Inc. (NASDAQ:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the three months ended February 29, 2016. All dollar amounts referenced herein are in United States dollars unless otherwise noted.
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

Intellipharmaceutics to Present at the 28th Annual ROTH Conference
GlobeNewswire - Tue Mar 08, 4:30PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the 28 Annual ROTH Conference on March 15, 2016. The presentation will take place at 2:00 P.M. (PT) at the Ritz Carlton Laguna Niguel, Orange County California.
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

Intellipharmaceutics to Present at the Noble Financial Capital Markets' 12th Annual Investor Conference
GlobeNewswire - Tue Jan 19, 9:00AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that the Company is scheduled to present at the Noble Financial Capital Markets' 12 Annual Investor Conference on January 20, 2016. The presentation will take place at 9:00 A.M. (EST) at the Club Med, Sandpiper Bay, Florida.
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

Intellipharmaceutics Up on Positive Rexista Oxycodone Data
Zacks Equity Research - Zacks Investment Research - Fri Jan 15, 3:45PM CST
Shares of Intellipharmaceutics International Inc. (IPCI) surged significantly after it announced that the bioequivalence trials on Rexista Oxycodone XR extended release tablets have demonstrated bioequivalence to Purdue Pharma's Oxycontin.
IPCI: 1.99 (+0.15), AERI: 17.42 (+0.07), CORT: 5.84 (+0.04), PCRX: 37.35 (+1.10)

Intellipharmaceutics Announces Successful Bioequivalence Results for Abuse Deterrent Rexista(TM) Oxycodone XR
GlobeNewswire - Thu Jan 14, 6:30AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I) ("Intellipharmaceutics" or the "Company", a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that pivotal bioequivalence trials of the Company's Rexista(TM) Oxycodone XR (abuse deterrent oxycodone hydrochloride) extended release tablets, dosed under fasted and fed conditions, had demonstrated bioequivalence to Oxycontin(R) (oxycodone hydrochloride) extended release tablets as manufactured and sold in the United States by Purdue Pharma LP. The study design was based on United States Food and Drug Administration ("FDA" recommendations and compared the lowest and highest strengths of exhibit batches of the Company's Rexista(TM) Oxycodone XR to the same strengths of Oxycontin(R). The results show that the ratios of the pharmacokinetic metrics, Cmax, AUC0-t and AUC0-f for Rexista(TM) vs. Oxycontin(R), are within the interval of 80% - 125% required by the FDA with a confidence level exceeding 90%.
I.TO: 2.36 (+0.12), IPCI: 1.99 (+0.15)

IntelliPharmaCeutics (IPCI) Rises: Stock Up 6.5% in Session
Zacks Equity Research - Zacks Investment Research - Tue Jan 12, 7:45AM CST
IntelliPharmaCeutics International Inc. (IPCI) was a big mover last session, as the company saw its shares rise over 6% on the day.
EARS: 4.19 (+0.18), IPCI: 1.99 (+0.15)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 87

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Berry Street Integrates AI with What Matters: Human Touch

Updated Category News Views 385

Health Meets AI at Berry Street In recent waves of news, Berry Street has decided to toss MyScribe, a standalone AI service, into its shopping cart and welcomed its brainwave behind it, Dr. Wasif Bokhari, into their corridors. Yep, they’ve snagged both the tech and the mind! It's the kind of move that makes you stop midway through your diner coffee. Here’s Berry...

Continue Reading
Flagship's £100M London Move to Ignite AI Ventures

Updated Category News Views 67

London Calling: Flagship's New Venture Flagship Pioneering, the brain behind bustling biotech ventures like Moderna, is planting its flag in London. They're launching Flagship Origination Lab, U.K., their first real gig outside good ol' Cambridge, Massachusetts. They're diving in headfirst, sprinkling a whopping £100 million to brew up AI-native platform companies. And...

Continue Reading
Bizzdesign Tops Gartner’s 2026 Enterprise Architecture List

Updated Category News Views 33

Enterprise Architecture’s Silent Backbone Sometimes it's the quiet operators like Bizzdesign that hijack the spotlight after years of steady steering. With the latest nod from Gartner, Bizzdesign is clearly on a tear in the enterprise architecture domain. In their 2026 Critical Capabilities report, Bizzdesign's products—Horizzon, Alfabet, and Hopex—secured top spots...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 44

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
KuCoin Unveils $1.1M USDT Black Friday Bonanza

Updated Category News Views 0

KuCoin's Festive Fireworks: Black Friday Bonanza Sometimes the crypto world feels like a carnival, and KuCoin's latest act is the $1.1 million USDT prize pool, rolling out as part of its 'Tis The Season holiday campaign. A move that matches the glitz of Tomorrowland Winter experiences, adding more sparkle to the crypto stage. Behind the Scenes of the KuCoin-Tomorrowland...

Continue Reading
ZTE Reinvents Energy for AI Data Centers

Updated Category News Views 25

The Great Race: Power and AI in Sync Here we are, neck-deep in the AI era, where the demand for raw computing power just won’t quit. With every data-hungry application and supercharged algorithm, companies are scrambling to keep up. But there’s a nasty little dragon in this fairy tale—energy efficiency. ZTE isn’t just acknowledging this beast; they’re ready to...

Continue Reading
Net Zero Efforts to Cost Europe €60B Annually by 2050

Updated Category News Views 38

Hefty Prices Loom Over Net Zero Commitments Well, strap in for a wallet buster, folks. Europe's largest players are staring down the barrel of a colossal €60 billion annual bill to clean up their carbon mess by 2050. That's the ticker in Senken's latest report, 'Pace of Change 2026.' Talks like these remind me there's no such thing as a free lunch, especially when...

Continue Reading
Sivers Semiconductors: Strategy Behind 2027 AGM Plans

Updated Category News Views 113

Setting the Stage for a Crucial Year Ah, the dance of corporate governance—an arena where maneuvering is an art. Sivers Semiconductors AB, a name that's becoming synonymous with innovation in the photonics and wireless solutions sector, is prepping for its 2027 Annual General Meeting. Ahead of this pivotal event, they're forming a Nomination Committee to shape future...

Continue Reading

Top 5 Most Recently Viewed Articles

Cypherpunk Technologies Boosts Zcash Holdings Significantly Year-Over-Year

Updated Category News Views 108

Cypherpunk Technologies Expands Zcash Accumulation CAMBRIDGE, Mass. — Cypherpunk Technologies Inc. (Nasdaq: CYPH), a company deeply engaged in privacy technology, has recently accelerated its efforts to accumulate Zcash, significantly boosting its treasury holdings. This move reflects their strategic commitment to enhancing their corporate asset portfolio and addressing...

Continue Reading
Insights from Access LIVE: The Future of Beverage Leadership

Updated Category News Views 253

Insights from Access LIVE: The Future of Beverage Leadership Leaders from the nation's largest distributors convened to share their insights on innovation, growth, and the future of the beverage alcohol industry. The session, known as "Wholesaler Power Hour — Market Drivers: Wholesale Leaders Blazing a Path to Success," took place on the LIVE Stage at Access LIVE 2025,...

Continue Reading
Understanding Microsoft's Competitive Edge in the Software Sector

Updated Category News Views 211

Dynamic Insights into Microsoft and Its Competitors In the rapidly evolving business landscape, a thorough examination of companies is vital for investors and enthusiasts alike. This article delves into a detailed comparative analysis of Microsoft (NASDAQ: MSFT) relative to its main competitors within the software industry. By evaluating essential financial metrics,...

Continue Reading
The Transformative Financial Journey of Pan American Silver Stock

Updated Category News Views 154

The Impact of Long-Term Investment in Pan American Silver Investing in stocks is often seen as a journey, and Pan American Silver (NYSE: PAAS) stands as a shining example of how patience can yield extraordinary rewards over the years. Over the last decade, Pan American Silver has surpassed market performance, boasting an annualized return of 22.95%, which is significantly...

Continue Reading
Linc Housing Initiates Construction of 90 Affordable Units

Updated Category News Views 219

Linc Housing Begins Construction on New Affordable Homes In a promising development for families in need, Linc Housing has commenced the construction of three new affordable apartment communities. This initiative will create 90 new homes specifically designed for low-income individuals and families. The timing could not be more critical, as communities grapple with an...

Continue Reading